These findings suggest that the combined WZB117 and anti-PD-L1 therapy effectively targets the glucose-competition/NSUN2 axis in HCC, enhancing CD8+ T cell anti-tumor activity while partially regulating HCC evolution through NSUN2-m5C modification. Here, NSUN2 is linked to neoplasm.